Results 11 to 20 of about 148,906 (304)
CA: A Cancer Journal for Clinicians, 1993 The etiology of Hodgkin's disease is unknown, and the identity of the normal counterpart of the malignant cell involved in Hodgkin's disease remains controversial. Yet, three of every four patients diagnosed with Hodgkin's disease will be cured. This success in treatment is due in large part to the application of modern oncologic techniques, such as ...
E L, Weinshel, B A, Peterson
exaly +8 more sources
Composite follicular lymphoma and classic Hodgkin lymphoma [PDF]
Journal of Pathology and Translational Medicine, 2022 Composite lymphoma is very rare and a combination of Hodgkin lymphoma and non-Hodgkin lymphoma and even histiocytic tumors can occur. Because of the unfamiliarity, not only can this cause diagnostic problems, but can also affect treatment plan. We report
Han-Na Kim +5 more
doaj +1 more source
Human Vaccines & Immunotherapeutics, 2023 Individuals who are immunocompromised (IC) due to therapy or underlying disease are at increased risk of herpes zoster (HZ). This study evaluates the public health impact of recombinant zoster vaccine (RZV) relative to no HZ vaccination for the ...
Desmond Curran +8 more
doaj +1 more source
Nodular lymphocyte predominant Hodgkin lymphoma behaves as a distinct clinical entity with good outcome: evidence from 14-year followup in the West of Scotland Cancer Network [PDF]
, 2011 Clinically and biologically, nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) has much more in common with germinal-center derived B-cell non-Hodgkin lymphoma (NHL) than with classical Hodgkin lymphoma (cHL).
Diehl V +8 more
core +1 more source
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. [PDF]
, 2016 Preclinical models suggest that histone deacetylase (HDAC) and mammalian target of rapamycin (mTOR) inhibitors have synergistic anticancer activity. We designed a phase I study to determine the safety, maximum tolerated dose (MTD), recommended phase II ...
Falchook, Gerald S. +17 more
core +2 more sources
GLUT1 expression patterns in different Hodgkin lymphoma subtypes and progressively transformed germinal centers [PDF]
, 2012 Background: Increased glycolytic activity is a hallmark of cancer, allowing staging and restaging with 18F-fluorodeoxyglucose-positron-emission-tomography (PET).
Agostinelli, Claudio +9 more
core +1 more source
Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma [PDF]
, 2016 Levels of plasma cell-free DNA (cfDNA) of a large series of children with classical Hodgkin lymphoma (cHL) were evaluated and analyzed at diagnosis and during chemotherapy treatment in relation with clinical characteristics.
Basso, Giuseppe +11 more
core +2 more sources
Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]
, 2012 Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Benz, Alexander +2 more
core +2 more sources
Креативная хирургия и онкология, 2018 Introduction. An urgent issue facing contemporary medicine is the problem of cancer. According to official Russian Federation statistical data, of the 2,132,050 deaths recorded in 2015, 286,900 of them resulted from cancer.
R. A. Maier +2 more
doaj +1 more source
Slovenian Journal of Public Health, 2021 With the aim of improving personalized treatment of patients on chemotherapy, the objective of the study was to assess the degree of association between selected Quality of life (QoL) indicators and both clinical and imaging cardiac status indicators ...
Geršak Blaž Matija +12 more
doaj +1 more source